Cargando…

Prognostic factors of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma: a real-world, large cohort study

Lung cancer remains the primary cause of cancer-related mortality worldwide. Several treatment modalities are available for lung cancer, including surgery, radiation, and chemotherapy. Among the chemotherapeutics available, afatinib has been shown to be effective for those with epidermal growth fact...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liang, Sheng-Kai, Lee, Meng-Rui, Liao, Wei-Yu, Ho, Chao-Chi, Ko, Jen-Chung, Shih, Jin-Yuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	Clinical Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5955108/ https://www.ncbi.nlm.nih.gov/pubmed/29805772 http://dx.doi.org/10.18632/oncotarget.25255

Ejemplares similares

Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma
por: Liang, Sheng-Kai, et al.
Publicado: (2017)

Afatinib as First-Line Treatment in Asian Patients with EGFR Mutation-Positive NSCLC: A Narrative Review of Real-World Evidence
por: Lu, Shun, et al.
Publicado: (2021)

Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study
por: Ho, Gwo-Fuang, et al.
Publicado: (2019)

Real-world analysis of first-line afatinib in patients with EGFR-mutant non-small cell lung cancer and brain metastasis: survival and prognostic factors
por: Kim, Jehun, et al.
Publicado: (2023)

Real-world experience of afatinib as first-line therapy for advanced EGFR mutation-positive non-small cell lung cancer in Korea
por: Lee, Sung Yong, et al.
Publicado: (2021)

First-line afatinib for the treatment of EGFR mutation-positive non-small-cell lung cancer in the ‘real-world’ clinical setting
por: Park, Keunchil, et al.
Publicado: (2019)

The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients
por: Wu, Shang-Gin, et al.
Publicado: (2016)

Afatinib in Treatment-Naive Patients With EGFR-Mutated Lung Adenocarcinoma With Brain Metastasis: A Case Series
por: Li, Shih-Hong, et al.
Publicado: (2015)

Local Consolidative Therapy May Have Prominent Clinical Efficacy in Patients with EGFR-Mutant Advanced Lung Adenocarcinoma Treated with First-Line Afatinib
por: Tsai, Ming-Ju, et al.
Publicado: (2023)

Real-world effectiveness of second-line Afatinib versus chemotherapy for the treatment of advanced lung squamous cell carcinoma in immunotherapy-naïve patients
por: Chen, You-Yi, et al.
Publicado: (2021)

Survival benefits from afatinib compared with gefitinib and erlotinib among patients with common EGFR mutation in first‐line setting
por: Kwok, Wang Chun, et al.
Publicado: (2022)

The Combination of Afatinib and Bevacizumab in Untreated EGFR-Mutated Advanced Lung Adenocarcinoma: A Multicenter Observational Study
por: Hsu, Ping-Chih, et al.
Publicado: (2020)

Afatinib and osimertinib in lung adenocarcinoma harbored EGFR T751_I759delinsS mutation: A case report
por: Fang, Yueh‐Fu, et al.
Publicado: (2021)

A real-world study of Afatinib plus ramucirumab in treatment-naïve, EGFR-mutated, non–small cell lung cancer
por: Huang, Chun-Yao, et al.
Publicado: (2023)

Efficacy and safety of afatinib in a Chinese population with advanced lung adenocarcinoma with sensitive EGFR mutations
por: Wang, Shouzheng, et al.
Publicado: (2019)

Real-world treatment of over 1600 Japanese patients with EGFR mutation-positive non-small cell lung cancer with daily afatinib
por: Tamura, Kazuo, et al.
Publicado: (2019)

A Novel Oncogenic Driver in a Lung Adenocarcinoma Patient Harboring an EGFR-KDD and Response to Afatinib
por: Chen, Dong, et al.
Publicado: (2020)

Anti-inflammatory effect of afatinib (an EGFR-TKI) on OGD-induced neuroinflammation
por: Chen, Yen-Ju, et al.
Publicado: (2019)

Correction to: Real-world treatment of over 1600 Japanese patients with EGFR mutation-positive non-small cell lung cancer with daily afatinib
por: Tamura, Kazuo, et al.
Publicado: (2019)

Efficacy and Safety of Afatinib in the Treatment of Advanced Non-Small-Cell Lung Cancer with EGFR Mutations: A Meta-Analysis of Real-World Evidence
por: Zhang, Lemeng, et al.
Publicado: (2021)

The effectiveness of afatinib in patients with lung adenocarcinoma harboring complex epidermal growth factor receptor mutation
por: Wu, Shang-Gin, et al.
Publicado: (2020)

Effectiveness and Tolerability of First-Line Afatinib for Advanced EGFR-Mutant Non-Small Cell Lung Cancer in Vietnam
por: Vu, Thanh Ha, et al.
Publicado: (2021)

A real-world study comparing perioperative chemotherapy and EGFR-tyrosine kinase inhibitors for treatment of resected stage III EGFR-mutant adenocarcinoma
por: Chen, Chieh-Lung, et al.
Publicado: (2023)

Treatment Options of First-Line Tyrosine Kinase Inhibitors and Subsequent Systemic Chemotherapy Agents for Advanced EGFR Mutant Lung Adenocarcinoma Patients: Implications From Taiwan Cancer Registry Cohort
por: Liang, Sheng-Kai, et al.
Publicado: (2021)

An EGFR-mutated Lung Adenocarcinoma Undergoing Squamous Cell Carcinoma Transformation Exhibited a Durable Response to Afatinib
por: Sato, Mitsuo, et al.
Publicado: (2018)

Long-lasting response to afatinib that persisted after treatment discontinuation in a case of EGFR-mutated lung adenocarcinoma
por: Yamanaka, Yumie, et al.
Publicado: (2019)

Blocking autophagy improves the anti-tumor activity of afatinib in lung adenocarcinoma with activating EGFR mutations in vitro and in vivo
por: Hu, Xiangxiang, et al.
Publicado: (2017)

Response to Afatinib in a Common EGFR-Mutated Lung Adenocarcinoma with a Very Rare Combination of Compound Mutations
por: Satoh, Hiroaki, et al.
Publicado: (2022)

Is there a role for sequential afatinib and osimertinib in patients with EGFR mutation?
por: Iwamoto, Natsuhiko, et al.
Publicado: (2022)

Letter to the editor concerning first-line therapy with afatinib – an irreversible EGFR TKI and overall survival of NSCLC patients with EGFR gene mutations
por: Krawczyk, Paweł, et al.
Publicado: (2015)

Short-course pembrolizumab and continuous afatinib therapy for recurrent or metastatic head and neck squamous cell carcinoma: a real-world data analysis
por: Kao, Hsiang-Fong, et al.
Publicado: (2022)

Lung Adenocarcinoma Patient Harboring EGFR-KDD Achieve Durable Response to Afatinib: A Case Report and Literature Review
por: Zhao, Lingling, et al.
Publicado: (2021)

EGFR-mutated pulmonary adenocarcinoma with concurrent PIK3CA mutation, and with acquired RET fusion and EGFR T790M mutation after afatinib therapy
por: Kim, Minhye, et al.
Publicado: (2021)

Final Report on Real-World Effectiveness of Sequential Afatinib and Osimertinib in EGFR-Positive Advanced Non–Small Cell Lung Cancer: Updated Analysis of the RESET Study
por: Kim, Taeyun, et al.
Publicado: (2023)

Author Correction: Anti-inflammatory effect of afatinib (an EGFR-TKI) on OGD-induced neuroinflammation
por: Chen, Yen-Ju, et al.
Publicado: (2021)

Afatinib for the Treatment of NSCLC with Uncommon EGFR Mutations: A Narrative Review
por: Jiang, Yingying, et al.
Publicado: (2023)

Observational Study of Sequential Afatinib and Osimertinib in EGFR Mutation-Positive NSCLC: Patients Treated with a 40-mg Starting Dose of Afatinib
por: Yamamoto, Nobuyuki, et al.
Publicado: (2019)

Differential significance of molecular subtypes which were classified into EGFR exon 19 deletion on the first line afatinib monotherapy
por: Tokudome, Nahomi, et al.
Publicado: (2020)

Afatinib as first-line treatment in patients with EGFR-mutated non-small cell lung cancer in routine clinical practice
por: Brückl, Wolfgang M., et al.
Publicado: (2021)

CNS efficacy of afatinib as first-line treatment in advanced non-small cell lung cancer patients with EGFR mutations
por: Kang, Liping, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ciefp5j1952p6tm4v95rmlavqh